MERLIN has now been added to EuroStemCell’s Connections. EuroStemCell is a European partnership of scientists, clinicians, ethicists, social scientists and science communicators. Launched in March 2010, the partnership unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science.
MERLIN researcher Gideon Hirschfield of the University of Birmingham gave a talk about current and future therapies for PSC to patients. Watch a video of the presentation here.
MERLIN researcher Steve Elliman of Orbsen Therapeutics presented at the 8th Annual UK MSC meeting hosted by REMEDI in Galway 29 – 30 Oct, 2014. To read more about the conference, and to see a list of the other speakers, click here.
A new page dedicated to related publications has now gone live on the MERLIN site. This page can be accessed by following this link, and it will be updated throughout the project.
MERLIN recently received coverage on the Primary Sclerosing Cholangitis Support website.
PSC Support is
the UK charity dedicated to helping people affected by Primary Sclerosing Cholangitis (PSC). PSC Support is run by a small team of volunteers, totally funded from charitable donations, and here to help anyone affected by Primary Sclerosing Cholangitis.
Our objectives are to:
- provide information and support to those affected by PSC.
- work with partners to promote awareness of PSC, current research and the need for organ donation.
- support PSC-related medical practitioners and researchers by:
- giving PSC patients access to the latest relevant medical information to promote patient participation in essential trials;
- providing grants towards projects that have specific target outcomes.
- develop effective partnerships between PSC Support and medical practitioners, researchers, policy makers and people affected by PSC.
You can find out more about their organisation here.
The Irish Times covered the MERLIN Project on April 22nd, 2014, in an article titled “Orbsen Therapeutics to take part in €6m liver disease clinical trial.”
Orbsen Therapeutics, a spin-out from NUI Galway’s Regenerative Medicine Institute (Remedi) has announced plans to partner with the University of Birmingham in a €6 million project to fight liver disease.
The stem cell research company, which was founded by Prof Frank Barry and Prof Tom O’Brien in 2006, will collaborate with the university on an EU FP7-funded project known by as Merlin (MEsynchymal stem cells to Reduce Liver INflammation). The project, which is led by Prof Phil Newsome, will advance Orbsen’s proprietary cell therapy to a Phase 2a clinical trial.
Please read the rest of the article here.
MERLIN partners meet in Birmingham, UK, on 10-11 February, 2014 to initiate the project.
- Joining up of EU's best expertise on this scale should benefit every year thousands of patients with diseases requi… t.co/8xQXuN63eo Time ago 2 Days via Hootsuite
- @wellcometrust asks a valid question here. What's your opinion? t.co/cjo5ZKZFbE Time ago 14 Days via Twitter Web Client
- This week @FP7Merlin researcher @DrDeeds3 of @Orbsen reports from #ISCTEU2018! t.co/W201EglEnK Time ago 14 Days via Twitter Web Client
Follow @fp7merlin on twitter.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 602363. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.